Molecular targeted therapies in small-cell lung cancer;Thérapies moléculaires ciblées dans le cancer du poumon à petites cellules

Bulletin du Cancer

Volumn 97, Issue 5, 2010, Pages 535-545

  Levy, A ^a   Malouf, G G ^a   Besse, B ^a   Massard, C ^a   Soria, J C ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Small cell lung cancer; Targeted therapy

Indexed keywords

2 [[1 (7 CHLORO 4 QUINOLINYL) 5 (2,6 DIMETHOXYPHENYL) 3 PYRAZOLYL]CARBONYLAMINO] 2 ADAMANTANECARBOXYLIC ACID; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; AFINITOR; BEVACIZUMAB; BORTEZOMIB; CARBOPLATIN; CEDIRANIB; CISPLATIN; CYCLOPHOSPHAMIDE; DASATINIB; DEHYDRODIDEMNIN B; DOXORUBICIN; ETOPOSIDE; EVEROLIMUS; GEFITINIB; IMATINIB; IRINOTECAN; LENALIDOMIDE; MARIMASTAT; MECLINERTANT; N (5 CHLORO 1,3 BENZODIOXOL 4 YL) 7 [2 (4 METHYL 1 PIPERAZINYL)ETHOXY] 5 (TETRAHYDRO 2H PYRAN 4 YLOXY) 4 QUINAZOLINAMINE; OBATOCLAX; OBLIMERSEN; PACLITAXEL; PLACEBO; SORAFENIB; TEMSIROLIMUS; THALIDOMIDE; TIPIFARNIB; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR;

ANGIOGENESIS; APOPTOSIS; BLOOD TRANSFUSION REACTION; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER SURVIVAL; CELL CYCLE; CEREBROVASCULAR ACCIDENT; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; HEART FAILURE; HEMATOLOGIC DISEASE; HUMAN; HYPERTENSION; IMMUNOTHERAPY; LUNG SMALL CELL CANCER; NEUTROPENIA; OUTCOME ASSESSMENT; PERIPHERAL NEUROPATHY; PNEUMONIA; QT PROLONGATION; REVIEW; SIGNAL TRANSDUCTION; THROMBOSIS; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; DRUG EFFECT; DRUG RESISTANCE; FEMALE; GENETICS; LUNG TUMOR; MALE; METABOLISM; METHODOLOGY; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; APOPTOSIS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; MALE; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; SMALL CELL LUNG CARCINOMA;

EID: 77953059217     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2010.1035     Document Type: Review

References (63)

1. American Cancer Society, Cancer facts and figures. Atlanta : American Cancer Society, 2007.
2. Navada S, Lai P, Schwartz A, Kalemkerian G. Temporal trends in small-cell lung cancer: analysis of the National surveillance, epidemiology and end-results (SEER) database. J Clin Oncol 2006; 24: 18S: (Abstract 7082).
3. Pujol JL, Daurès JP, Rivière A, Quoix E, Westeel V, Quantin X, et al. Etoposide plus cisplatin with or without the combination of 4′-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: a French Federation of Cancer Institutes multicenter phase III randomized study. J Natl Cancer Inst 2001; 21: 300-308
4. Patel S, Macdonald OK, Suntharalingam M. Evaluation of the use of prophylactic cranial irradiation in small-cell lung cancer. Cancer 2009; 15: 842-850
5. Murray N, Turrisi 3rd AT. A review of first-line treatment for small-cell lung cancer. J Thorac Oncol 2006; 1: 270-278 (Pubitemid 47181446)
6. Woll PJ, Rozengurt E. A neuropeptide antagonist that inhibits the growth of small-cell lung cancer in vitro. Cancer Res 1990; 50: 3968-3973 (Pubitemid 20225615)
7. Roelle S, Grosse R, Buech T, Chubanov V, Gudermann T. Essential role of Pyk2 and Src-kinase activation in neuropeptide-induced proliferation of small-cell lung cancer cells. Oncogene 2008; 27: 1737-1748 (Pubitemid 351380271)
8. Ma PC, Kijima T, Maulik G, Fox EA, Sattler M, Griffin JD, et al. c-MET mutational analysis in small-cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res 2003; 63: 6272-6281 (Pubitemid 37255174)
9. Lévy A, Sauvin LA, Massard C, Soria JC. Everolimus (RAD001) and solid tumours: a 2008 summary. Bull Cancer 2008; 95: 1205-1211
10. Vogler M, Butterworth M, Dyer MJ, Cohen GM, et al. Concurrent upregulation of Bcl-xl and Bcl-2A1 induces ∼1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. Blood 2009; 113: 4403-4413
11. Sarvesvaran J, Going JJ, Milroy R, Kaye SB, Keith WN. Is small-cell lung cancer the perfect target for anti-telomerase treatment? Carcinogenesis 1999; 20: 1649-1651
12. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 2000; 18: 1135-1149 (Pubitemid 30123793)
13. Weinstein IB. Cancer. Addiction to oncogenes: the Achilles heal of cancer. Science 2002; 297: 63-64
14. Maulik G, Bharti A, Khan E, Broderick RJ, Kijima T, Salgia R. Modulation of c-Kit/SCF pathway leads to alterations in topoisomerase-I activity in small-cell lung cancer. J Environ Pathol Toxicol Oncol 2004; 23: 237-251 (Pubitemid 41737139)
15. Soria JC, Johnson BE, Chevalier TL. Imatinib in small-cell lung cancer. Lung Cancer 2003; 41 (Suppl 1) : S49-53.
16. Dy GK, Miller AA, Mandrekar SJ, Aubry MC, Langdon Jr RM, Morton RF, et al. A phase II trial of imatinib (ST1571) in patients with c-Kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study. Ann Oncol 2005; 16: 1811-1816.
17. Krug LM, Crapanzano JP, Azzoli CG, Miller VA, Rizvi N, Gomez J, et al. Imatinib mesylate lacks activity in small-cell lung carcinoma expressing c-Kit protein: a phase II clinical trial. Cancer 2005; 103: 2128-2131
18. Schneider B, Gadgeel S, Ramnath N, et al. Phase II trial of imatinib maintenance therapy after irinotecan and cisplatin in patients with c-Kit positive extensive-stage small-cell lung cancer (ES CBPC). J Clin Oncol 2006; 24: 17089.
19. Takigawa N, Takeyama M, Kozuki T, Shibayama T, Hisamoto A, Kiura K, et al. Combination of SN-38 with gefitinib or imatinib overcomes SN-38-resistant small-cell lung cancer cells. Oncol Rep 2007; 17: 983-987
20. Johnson FM, Krug LM, Tran HT, Shoaf S, Prieto V, Tamboli P, et al. Phase I studies of imatinib mesylate combined with cisplatin and irinotecan in patients with small-cell lung carcinoma. Cancer 2006; 106: 366-374 (Pubitemid 43100446)
21. Spigel DR, Hainsworth JD, Simons L, Meng C, Burris 3rd HA, Yardley DA, et al. Irinotecan, carboplatin and imatinib in untreated extensive-stage small-cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network. J Thorac Oncol 2007; 2: 54-861.
22. O'Hare T, Eide CA, Deininger MW. New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check. Expert Opin Investig Drugs 2008; 17: 865-878 (Pubitemid 351864324)
23. Lee D, Gautschi O. Clinical development of SRC tyrosine-kinase inhibitors in lung cancer. Clin Lung Cancer 2006; 7: 381-384 (Pubitemid 44043546)
24. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271-2281
25. Heymach JV, Johnson DH, Khuri FR, Safran H, Schlabach LL, Yunus F, et al. Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer. Ann Oncol 2004; 15: 1187-1193
26. Moore AM, Einhorn LH, Estes D, Govindan R, Axelson J, Vinson J, et al. Gefitinib in patients with chemosensitive and chemorefractory relapsed small-cell cancers: a Hoosier Oncology Group phase II trial. Lung Cancer 2006; 52: 93-97 (Pubitemid 43340205)
27. Moody TW, Chan D, Fahrenkrug J, Jensen RT. Neuropeptides as autocrine growth factors in cancer cells. Curr Pharm Des 2003; 9: 495-509. (Pubitemid 36131740)
28. Pandya KJ, Dahlberg S, Hidalgo M, Cohen RB, Lee MW, Schiller JH, et al. A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500). J Thorac Oncol 2007; 2: 1036-1041 (Pubitemid 350059580)
29. Owonikoko TK. Phase II study of RAD001 (Everolimus) in previously treated small-cell lung cancer (SCLC). ASCO Abstract no 19017 2008 ASCO Annual Meeting-Category: Lung Cancer-Metastatic Lung Cancer.
30. Rudin CM, Otterson GA, Mauer AM, Villalona, Calero MA, Tomek R, et al. A pilot trial of G3139, a Bcl-2 antisense oligonucleotide and paclitaxel in patients with chemorefractory small-cell lung cancer. Ann Oncol 2007; 13: 539-545
31. Rudin CM, Kozloff M, Hoffman P, Edelman MJ, Karnauskas R, Tomek R, et al. Phase I study of G3139, a Bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer. J Clin Oncol 2004; 22: 1110-1117
32. Rudin CM, Salgia R, Wang X, Hodgson LD, Masters GA, Green M, et al. Randomized phase II Study of carboplatin and etoposide with or without the Bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103. J Clin Oncol 2008; 26: 870-876
33. Li J, Viallet J, Haura EB. A small molecule pan-Bcl-2 family inhibitor, GX15-070, induces apoptosis and enhances cisplatin-induced apoptosis in non-small-cell lung cancer cells. Cancer Chemother Pharmacol 2008; 61: 525-534
34. Davies AM, Lara Jr PN, Mack PC, Gandara DR. Incorporating bortezomib into the treatment of lung cancer. Clin Cancer Res 2007; 13: S4647-S51.
35. Lara PN Jr, Chansky K, Davies AM, Franklin WA, Gumerlock PH, Guaglianone PP, et al. Bortezomib (PS-341) in relapsed or refractory extensive stage small-cell lung cancer: a Southwest Oncology Group phase II trial (S0327). J Thorac Oncol 2006: 996-1001.
36. Cuadrado A, Garcia-Fernandez LF, Gonzalez L, Suarez Y, Losada A, Alcaide V, et al. Aplidin induces apoptosis in human cancer cells via glutathione depletion and sustained activation of the epidermal growth factor receptor, Src, JNK and p38 MAPK. J Biol Chem 2003; 278: 241-250
37. Eisen T, Thatcher N, Leyvraz S, Miller Jr WH, Couture F, Lorigan P, et al. Phase II study of weekly plitidepsin as second-line therapy for small-cell lung cancer. Lung Cancer 2009; 64: 60-65
38. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
39. Delmotte P, Martin B, Paesmans M, Lafitte JJ, Sculier JP, et al. VEGF and survival of patients with lung cancer: a systematic literature review and meta-analysis. Rev Mal Respir 2002; 19: 577-584 (Pubitemid 35303646)
40. Raefsky E, Spigel DR, Greco FA, Petrone D, Hainsworth JD, et al. Irinotecan (I), carboplatin (C), and radiotherapy (RT) followed by bevacizumab (B) in the treatment of limited-stage small-cell lung cancer (CBPC): a phase II trial of the Minnie Pearl Cancer Research Network. Proc Am Soc Clin Oncol 2005; 23: 7050.
41. Barron H, MedWatch safety alert 2007. Available at: http://www.fda.gov/ downloads/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ UCM153953.pdf
42. Patton JF, Spigel DR, Greco FA, et al. Irinotecan (I), carboplatin (C) and radiotherapy (RT) followed by maintenance bevacizumab (B) in the treatment (tx) of limited-stage small-cell lung cancer (LSSCLC): update of a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2006; 24: 385s (abstract).
43. Ready N, Dudek AZ, Wang XF, et al. CALGB 30306: a phase II study of cisplatin (C), irinotecan (I) and bevacizumab (B) for untreated extensive stage small-cell lung cancer (ES-CBPC). Proc Am Soc Clin Oncol 2007; 25: 7563.
44. Sandler A, Szwaric S, Dowlati A, et al. A phase II study of cisplatin (P) plus etoposide (E) plus bevacizumab (B) for previously untreated extensive stage small-cell lung cancer (CBPC) (E3501): a trial of the Eastern Cooperative Oncology Group. Proc Am Soc Clin Oncol 2007; 25: 7564.
45. Spigel D, Hainsworth JD, Saez R, Greco FA, et al. Phase II trial of irinotecan, carboplatin and bevacizumab in patients with extensive-stage small-cell lung cancer. Proc Am Soc Clin Oncol 2007; 25: 18130.
46. Bachelot T, Ray-Coquard I, Cassier P, Blay JY. Angiogenesis and breast cancer. Bull Cancer 2007; 94 (Spec No) : S203-S10.
47. Pujol JL, Breton JL, Gervais R, Tanguy ML, Quoix E, David P, et al. Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC cleo04 IFCT 00-01. J Clin Oncol 2007; 25: 3945-3951
48. Lee SW, Woll PJ, James LE, Ali SR, Hackshaw A, et al. A phase III randomised, double blind, placebo controlled trial of etoposide/carboplatin with or without thalidomide in advanced small-cell lung cancer (CBPC). J Thor Oncol 2007; 2: S306.
49. Dowlati A, Subbiah S, Cooney M, Rutherford K, Mekhail T, Fu P, et al. Phase II trial of thalidomide as maintenance therapy for extensive stage small-cell lung cancer after response to chemotherapy. Lung Cancer 2007; 56: 377-381
50. Shepherd FA, Giaccone G, Seymour L, Debruyne C, Bezjak A, Hirsh V, et al. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 2002; 20: 4434-4439
51. Wells S, Gosnell J, Gagel R, et al. Vandetanib in metastatic hereditary medullary thyroid cancer: follow-up results of an open-label phase II trial. J Clin Oncol 2007. ASCO Annual Meeting Proceedings Part I. Vol 25, no 18S, 2007: 6018.
52. Arnold AM, Seymour L, Smylie M, et al. Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20. J Clin Oncol 2007; 25: 4278-4284
53. Gitlitz BJ, Glisson BS, Moon J, et al. Sorafenib in patients with platinum (plat) treated extensive stage small-cell lung cancer (E-CBPC): a SWOG (S0435) phase II trial. Proc Am Soc Clin Onco 2008; 26: 8039.
54. Ramalingam S. Cediranib (AZD2171) for the treatment of recurrent small-cell lung cancer (SCLC): a California consortium phase II study (NCI # 7097). ASCO Meeting Abstracts 2008; 26: 8078.
55. Kelly K, Crowley JJ, Bunn Jr PA, Hazuka MB, Beasley K, Upchurch C, et al. Role of recombinant interferon alfa-2a maintenance in patients with limited-stage small-cell lung cancer responding to concurrent chemoradiation: a Southwest Oncology Group study. J Clin Oncol 1995; 13: 2924-2930
56. Giaccone G, Debruyne C, Felip E, Chapman PB, Grant SC, Millward M, et al. Phase III study of adjuvant vaccination with Bec 2/bacille Calmette Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study). J Clin Oncol 2005; 23: 6854-6864
57. Harper-Wynne CL, Sumpter K, O'Brien MER, et al. Addition of SRL172 (Mycobacterium Vaccae) to standard chemotherapy in small-cell lung cancer (SCLC) confers no survival benefit: results of a randomized multicenter study. Lung Cancer 2003; 41: S181 (abstract).
58. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005; 435: 677-681
59. Griffiths R, Lorigan P, Thatcher N, Blackhall F. Update on targeted therapies for small-cell carcinoma of the lung. Targ oncol 2008; 3: 205-215
60. Krug LM, Ragupathi G, Hood C, Kris MG, Miller VA, Allen JR, et al. Vaccination of patients with small-cell lung cancer with synthetic fucosyl GM-1 conjugated to keyhole limpet hemocyanin. Clin Cancer Res 2004; 10: 6094-6100 (Pubitemid 39287514)
61. Ma PC, Tretiakova MS, Nallasura V, Jagadeeswaran R, Husain AN, Salgia R. Downstream signalling and specific inhibition of c-MET/HGF pathway in small-cell lung cancer: implications for tumour invasion. Br J Cancer 2007; 97: 368-377 (Pubitemid 47196754)
62. Vestergaard J, Pedersen MW, Pedersen N, Ensinger C, Tümer Z, Tommerup N, et al. Hedgehog signaling in small-cell lung cancer: frequent in vivo but a rare event in vitro. Lung Cancer 2006; 52: 281-290 (Pubitemid 43674545)
63. Tran HT. Correlation between plasma cytokine/angiogenic factors (C/AF) and signaling pathways activation from baseline tumour biopsy specimens in patients with advanced non-small cell lung cancer (NSCLC): preliminary analysis from the Biomarker-based Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) Clinical Study. ASCO Meeting Abstracts 2008; 26: 8010.